Yoel Kloog

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Rats
Mice

Physiology

Anatomy

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Starinsky-Elbaz Sigal; Faigenbloom Lior; Friedman Eitan; Stein Reuven; Kloog Yoel
The pre-GAP-related domain of neurofibromin regulates cell migration through the LIM kinase/cofilin pathway.
Kofer-Geles Merav; Gottfried Irit; Haklai Roni; Elad-Zefadia Galit; Kloog Yoel; Ashery Uri
Rasosomes spread Ras signals from plasma membrane 'hotspots'.
Rechavi Oded; Erlich Yaniv; Amram Hila; Flomenblit Lena; Karginov Fedor V; Goldstein Itamar; Hannon Gregory J; Kloog Yoel
Cell contact-dependent acquisition of cellular and viral nonautonomously encoded small RNAs.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Yoel Kloog (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Starinsky-Elbaz Sigal; Faigenbloom Lior; Friedman Eitan; Stein Reuven; Kloog Yoel
The pre-GAP-related domain of neurofibromin regulates cell migration through the LIM kinase/cofilin pathway.
Molecular and cellular neurosciences 2009;42(4):278-87.
2009: Kofer-Geles Merav; Gottfried Irit; Haklai Roni; Elad-Zefadia Galit; Kloog Yoel; Ashery Uri
Rasosomes spread Ras signals from plasma membrane 'hotspots'.
Biochimica et biophysica acta 2009;1793(11):1691-702.
2009: Rechavi Oded; Erlich Yaniv; Amram Hila; Flomenblit Lena; Karginov Fedor V; Goldstein Itamar; Hannon Gregory J; Kloog Yoel
Cell contact-dependent acquisition of cellular and viral nonautonomously encoded small RNAs.
Genes & development 2009;23(16):1971-9.
2009: Mor Adi; Kloog Yoel; Keren Gad; George Jacob
Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice.
European journal of pharmacology 2009;616(1-3):301-5.
2009: Kraitzer Amir; Kloog Yoel; Zilberman Meital
Novel farnesylthiosalicylate (FTS)-eluting composite structures.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2009;37(3-4):351-62.
2009: Rechavi Oded; Goldstein Itamar; Kloog Yoel
Intercellular exchange of proteins: the immune cell habit of sharing.
FEBS letters 2009;583(11):1792-9.
2009: Pando Rakefet; Cheporko Yelena; Haklai Ronit; Maysel-Auslender Sofia; Keren Gad; George Jacob; Porat Eyal; Sagie Alex; Kloog Yoel; Hochhauser Edith
Ras inhibition attenuates myocardial ischemia-reperfusion injury.
Biochemical pharmacology 2009;77(10):1593-601.
2009: Rechavi Oded; Kloog Yoel
Prion and anti-codon usage: does infectious PrP alter tRNA abundance to induce misfolding of PrP?
Medical hypotheses 2009;72(2):193-5.
2009: Goldberg Liat; Haklai Roni; Bauer Victor; Heiss Aaron; Kloog Yoel
New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
Journal of medicinal chemistry 2009;52(1):197-205.
2008: Goldberg Liat; Ocherashvilli Aharon; Daniels Dianne; Last David; Cohen Zvi R; Tamar Gregory; Kloog Yoel; Mardor Yael
Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: a convection-enhanced drug delivery study in rats.
Molecular cancer therapeutics 2008;7(11):3609-16.
2008: Rotshenker Shlomo; Reichert Fanny; Gitik Miri; Haklai Ronit; Elad-Sfadia Galit; Kloog Yoel
Galectin-3/MAC-2, Ras and PI3K activate complement receptor-3 and scavenger receptor-AI/II mediated myelin phagocytosis in microglia.
Glia 2008;56(15):1607-13.
2008: Even-Tzur Nurit; Kloog Yoel; Wolf Michael; Elad David
Mucus secretion and cytoskeletal modifications in cultured nasal epithelial cells exposed to wall shear stresses.
Biophysical journal 2008;95(6):2998-3008.
2008: Shalom-Feuerstein Ruby; Plowman Sarah J; Rotblat Barak; Ariotti Nicholas; Tian Tianhai; Hancock John F; Kloog Yoel
K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3.
Cancer research 2008;68(16):6608-16.
2008: Mor Adi; Keren Gad; Kloog Yoel; George Jacob
N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells.
European journal of immunology 2008;38(6):1493-502.
2008: Shalom-Feuerstein Ruby; Levy Ran; Makovski Victoria; Raz Avraham; Kloog Yoel
Galectin-3 regulates RasGRP4-mediated activation of N-Ras and H-Ras.
Biochimica et biophysica acta 2008;1783(6):985-93.
2008: Kraitzer Amir; Kloog Yoel; Zilberman Meital
Approaches for prevention of restenosis.
Journal of biomedical materials research. Part B, Applied biomaterials 2008;85(2):583-603.
2008: Belanis Liron; Plowman Sarah J; Rotblat Barak; Hancock John F; Kloog Yoel
Galectin-1 is a novel structural component and a major regulator of h-ras nanoclusters.
Molecular biology of the cell 2008;19(4):1404-14.
2008: Zvibel Isabel; Bar-Zohar Dan; Kloog Yoel; Oren Ran; Reif Shimon
The effect of Ras inhibition on the proliferation, apoptosis and matrix metalloproteases activity in rat hepatic stellate cells.
Digestive diseases and sciences 2008;53(4):1048-53.
2008: Porat-Shliom Natalie; Kloog Yoel; Donaldson Julie G
A unique platform for H-Ras signaling involving clathrin-independent endocytosis.
Molecular biology of the cell 2008;19(3):765-75.
2008: Blum Roy; Cox Adrienne D; Kloog Yoel
Inhibitors of chronically active ras: potential for treatment of human malignancies.
Recent patents on anti-cancer drug discovery 2008;3(1):31-47.
2008: Haklai Roni; Elad-Sfadia Galit; Egozi Yaakov; Kloog Yoel
Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
Cancer chemotherapy and pharmacology 2008;61(1):89-96.
2008: Rotblat Barak; Ehrlich Marcello; Haklai Roni; Kloog Yoel
The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
Methods in enzymology 2008;439():467-89.
2007: Marciano Daniele; Shohami Esther; Kloog Yoel; Alexandrovitch Alexander; Brandeis Rachel; Goelman Gadi
Neuroprotective effects of the Ras inhibitor S-trans-trans-farnesylthiosalicylic acid, measured by diffusion-weighted imaging after traumatic brain injury in rats.
Journal of neurotrauma 2007;24(8):1378-86.
2007: Zundelevich Adi; Elad-Sfadia Galit; Haklai Ronit; Kloog Yoel
Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid).
Molecular cancer therapeutics 2007;6(6):1765-73.
2007: Shapira S; Barkan B; Friedman E; Kloog Y; Stein R
The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways.
Cell death and differentiation 2007;14(5):895-906.
2007: Blum Roy; Elkon Ran; Yaari Shira; Zundelevich Adi; Jacob-Hirsch Jasmine; Rechavi Gideon; Shamir Ron; Kloog Yoel
Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Cancer research 2007;67(7):3320-8.
2007: Rechavi Oded; Goldstein Itamar; Vernitsky Helly; Rotblat Barak; Kloog Yoel
Intercellular transfer of oncogenic H-Ras at the immunological synapse.
PloS one 2007;2(11):e1204.
2006: Goldberg Liat; Kloog Yoel
A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration.
Cancer research 2006;66(24):11709-17.
2006: Henis Yoav I; Rotblat Barak; Kloog Yoel
FRAP beam-size analysis to measure palmitoylation-dependent membrane association dynamics and microdomain partitioning of Ras proteins.
Methods (San Diego, Calif.) 2006;40(2):183-90.
2006: Barkan Batya; Starinsky Sigal; Friedman Eitan; Stein Reuven; Kloog Yoel
The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(18):5533-42.
2006: Blum Roy; Jacob-Hirsch Jasmine; Rechavi Gideon; Kloog Yoel
Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis.
Molecular cancer therapeutics 2006;5(9):2337-47.
2006: Ashery Uri; Yizhar Ofer; Rotblat Barak; Kloog Yoel
Nonconventional trafficking of Ras associated with Ras signal organization.
Traffic (Copenhagen, Denmark) 2006;7(9):119-26.
2006: Erlich Shlomit; Tal-Or Pazit; Liebling Ronit; Blum Roy; Karunagaran Devarajan; Kloog Yoel; Pinkas-Kramarski Ronit
Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells.
Biochemical pharmacology 2006;72(4):427-36.
2006: Tal-Or Pazit; Erlich Shlomit; Porat-Shliom Natalie; Goldshmit Yona; Ben-Baruch Gilad; Shaharabani Ezra; Kloog Yoel; Pinkas-Kramarski Ronit
Ligand-independent regulation of ErbB4 receptor phosphorylation by activated Ras.
Journal of cellular biochemistry 2006;98(6):1482-94.
2006: Blum Roy; Nakdimon Itay; Goldberg Liat; Elkon Ran; Shamir Ron; Rechavi Gideon; Kloog Yoel
E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition.
International journal of cancer. Journal international du cancer 2006;119(3):527-38.
2006: Ashery Uri; Yizhar Ofer; Rotblat Barak; Elad-Sfadia Galit; Barkan Batya; Haklai Roni; Kloog Yoel
Spatiotemporal organization of Ras signaling: rasosomes and the galectin switch.
Cellular and molecular neurobiology 2006;26(4-6):471-95.
2006: Rotblat Barak; Yizhar Ofer; Haklai Roni; Ashery Uri; Kloog Yoel
Ras and its signals diffuse through the cell on randomly moving nanoparticles.
Cancer research 2006;66(4):1974-81.
2006: Beiner M E; Niv H; Haklai R; Elad-Sfadia G; Kloog Y; Ben-Baruch G
Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16 Suppl 1():200-6.
2005: Blum Roy; Kloog Yoel
Tailoring Ras-pathway--inhibitor combinations for cancer therapy.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2005;8(6):369-80.
2005: Kafri Michal; Kloog Yoel; Korczyn Amos D; Ferdman-Aronovich Ramona; Drory Vivian; Katzav Aviva; Wirguin Itzhak; Chapman Joab
Inhibition of Ras attenuates the course of experimental autoimmune neuritis.
Journal of neuroimmunology 2005;168(1-2):46-55.
2005: Kfir Shiri; Ehrlich Marcelo; Goldshmid Ayelet; Liu Xuedong; Kloog Yoel; Henis Yoav I
Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling.
Molecular and cellular biology 2005;25(18):8239-50.
2005: Shalom-Feuerstein Ruby; Cooks Tomer; Raz Avraham; Kloog Yoel
Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells.
Cancer research 2005;65(16):7292-300.
2005: Roy Sandrine; Plowman Sarah; Rotblat Barak; Prior Ian A; Muncke Cornelia; Grainger Sarah; Parton Robert G; Henis Yoav I; Kloog Yoel; Hancock John F
Individual palmitoyl residues serve distinct roles in H-ras trafficking, microlocalization, and signaling.
Molecular and cellular biology 2005;25(15):6722-33.
2005: Khwaja Arif; Sharpe Claire C; Noor Mazhar; Kloog Yoel; Hendry Bruce M
The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid.
Kidney international 2005;68(2):474-86.
2005: Yaari Shira; Jacob-Hirsch Jasmine; Amariglio Ninette; Haklai Ronit; Rechavi Gideon; Kloog Yoel
Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4321-30.
2005: Blum Roy; Jacob-Hirsch Jasmine; Amariglio Ninette; Rechavi Gideon; Kloog Yoel
Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death.
Cancer research 2005;65(3):999-1006.
2005: Aronovich Ramona; Gurwitz David; Kloog Yoel; Chapman Joab
Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms.
Immunobiology 2005;210(10):781-8.
2004: Halaschek-Wiener Julius; Wacheck Volker; Kloog Yoel; Jansen Burkhard
Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells.
Cellular signalling 2004;16(11):1319-27.
2004: Reif Shimon; Aeed Hussein; Shilo Yael; Reich Reuven; Kloog Yoel; Kweon Young Oh; Bruck Rafael
Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid.
Journal of hepatology 2004;41(2):235-41.
2004: Rotblat Barak; Prior Ian A; Muncke Cornelia; Parton Robert G; Kloog Yoel; Henis Yoav I; Hancock John F
Three separable domains regulate GTP-dependent association of H-ras with the plasma membrane.
Molecular and cellular biology 2004;24(15):6799-810.
2004: Kloog Yoel; Cox Adrienne D
Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs.
Seminars in cancer biology 2004;14(4):253-61.
2004: Elad-Sfadia Galit; Haklai Roni; Balan Eyal; Kloog Yoel
Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity.
The Journal of biological chemistry 2004;279(33):34922-30.
2004: Rotblat Barak; Niv Hagit; André Sabine; Kaltner Herbert; Gabius Hans-Joachim; Kloog Yoel
Galectin-1(L11A) predicted from a computed galectin-1 farnesyl-binding pocket selectively inhibits Ras-GTP.
Cancer research 2004;64(9):3112-8.
2004: George Jacob; Sack Jessica; Barshack Iris; Keren Pnina; Goldberg Iris; Haklai Roni; Elad-Sfadia Galit; Kloog Yoel; Keren Gad
Inhibition of intimal thickening in the rat carotid artery injury model by a nontoxic Ras inhibitor.
Arteriosclerosis, thrombosis, and vascular biology 2004;24(2):363-8.
2004: Shalom-Feuerstein R; Lindenboim L; Stein R; Cox A D; Kloog Y
Restoration of sensitivity to anoikis in Ras-transformed rat intestinal epithelial cells by a Ras inhibitor.
Cell death and differentiation 2004;11(2):244-7.
2003: Grossman R; Shohami E; Alexandrovich A; Yatsiv I; Kloog Y; Biegon A
Increase in peripheral benzodiazepine receptors and loss of glutamate NMDA receptors in a mouse model of closed head injury: a quantitative autoradiographic study.
NeuroImage 2003;20(4):1971-81.
2003: Dietrich Alexander; Scheer Alexander; Illenberger Daria; Kloog Yoel; Henis Yoav I; Gierschik Peter
Studies on G-protein alpha.betagamma heterotrimer formation reveal a putative S-prenyl-binding site in the alpha subunit.
The Biochemical journal 2003;376(Pt 2):449-56.
2003: Shohami Esther; Yatsiv Ido; Alexandrovich Alexander; Haklai Roni; Elad-Sfadia Galit; Grossman Rachel; Biegon Anat; Kloog Yoel
The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid exerts long-lasting neuroprotection in a mouse closed head injury model.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2003;23(6):728-38.
2003: Clarke Helen C; Kocher Hemant M; Khwaja Arif; Kloog Yoel; Cook H Terence; Hendry Bruce M
Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis.
Journal of the American Society of Nephrology : JASN 2003;14(4):848-54.
2003: Illenberger Daria; Walliser Claudia; Strobel Joachim; Gutman Orit; Niv Hagit; Gaidzik Verena; Kloog Yoel; Gierschik Peter; Henis Yoav I
Rac2 regulation of phospholipase C-beta 2 activity and mode of membrane interactions in intact cells.
The Journal of biological chemistry 2003;278(10):8645-52.
2003: Halaschek-Wiener Julius; Kloog Yoel; Wacheck Volker; Jansen Burkhard
Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo.
The Journal of investigative dermatology 2003;120(1):109-15.
2003: Katzav Aviva; Kloog Yoel; Korczyn Amos D; Molina Vered; Blank Miri; Shoenfeld Yehuda; Chapman Joab
Inhibition of ras by farnesylthiosalicylate significantly reduces the levels of autoantibodies in two animal models of the antiphospholipid syndrome.
Immunobiology 2003;207(1):47-50.
2002: Elad-Sfadia Galit; Haklai Roni; Ballan Eyal; Gabius Hans-Joachim; Kloog Yoel
Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase.
The Journal of biological chemistry 2002;277(40):37169-75.
2002: Niv Hagit; Gutman Orit; Kloog Yoel; Henis Yoav I
Activated K-Ras and H-Ras display different interactions with saturable nonraft sites at the surface of live cells.
The Journal of cell biology 2002;157(5):865-72.
2002: George Jacob; Afek Arnon; Keren Pnina; Herz Itzhak; Goldberg Iris; Haklai Roni; Kloog Yoel; Keren Gad
Functional inhibition of Ras by S-trans,trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice.
Circulation 2002;105(20):2416-22.
2002: Gana-Weisz Mali; Halaschek-Wiener Julius; Jansen Burkhard; Elad Galit; Haklai Ronit; Kloog Yoel
The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(2):555-65.
2001: Katzav A; Kloog Y; Korczyn A D; Niv H; Karussis D M; Wang N; Rabinowitz R; Blank M; Shoenfeld Y; Chapman J
Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS).
Clinical and experimental immunology 2001;126(3):570-7.
2001: Paz A; Haklai R; Elad-Sfadia G; Ballan E; Kloog Y
Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation.
Oncogene 2001;20(51):7486-93.
2001: Karussis D; Abramsky O; Grigoriadis N; Chapman J; Mizrachi-Koll R; Niv H; Kloog Y
The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis.
Journal of neuroimmunology 2001;120(1-2):1-9.
2000: Liu X; Sun Y; Ehrlich M; Lu T; Kloog Y; Weinberg R A; Lodish H F; Henis Y I
Disruption of TGF-beta growth inhibition by oncogenic ras is linked to p27Kip1 mislocalization.
Oncogene 2000;19(51):5926-35.
2000: Kloog Y; Cox A D
RAS inhibitors: potential for cancer therapeutics.
Molecular medicine today 2000;6(10):398-402.
2000: Halaschek-Wiener J; Wacheck V; Schlagbauer-Wadl H; Wolff K; Kloog Y; Jansen B
A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells.
Molecular medicine (Cambridge, Mass.) 2000;6(8):693-704.
1999: Reif S; Weis B; Aeed H; Gana-Weis M; Zaidel L; Avni Y; Romanelli R G; Pinzani M; Kloog Y; Bruck R
The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.
Journal of hepatology 1999;31(6):1053-61.
1999: Elad G; Paz A; Haklai R; Marciano D; Cox A; Kloog Y
Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid.
Biochimica et biophysica acta 1999;1452(3):228-42.
1999: Jansen B; Heere-Ress E; Schlagbauer-Wadl H; Halaschek-Wiener J; Waltering S; Moll I; Pehamberger H; Marciano D; Kloog Y; Wolff K
Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice.
Journal of molecular medicine (Berlin, Germany) 1999;77(11):792-7.
1999: Jansen B; Schlagbauer-Wadl H; Kahr H; Heere-Ress E; Mayer B X; Eichler H; Pehamberger H; Gana-Weisz M; Ben-David E; Kloog Y; Wolff K
Novel Ras antagonist blocks human melanoma growth.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(24):14019-24.
1999: Tisch-Idelson D; Sharabani M; Kloog Y; Aviram I
Stimulation of neutrophils by prenylcysteine analogs: Ca(2+) release and influx.
Biochimica et biophysica acta 1999;1451(1):187-95.
1999: Weisz B; Giehl K; Gana-Weisz M; Egozi Y; Ben-Baruch G; Marciano D; Gierschik P; Kloog Y
A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice.
Oncogene 1999;18(16):2579-88.
1999: Egozi Y; Weisz B; Gana-Weisz M; Ben-Baruch G; Kloog Y
Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist.
International journal of cancer. Journal international du cancer 1999;80(6):911-8.
1999: Niv H; Gutman O; Henis Y I; Kloog Y
Membrane interactions of a constitutively active GFP-Ki-Ras 4B and their role in signaling. Evidence from lateral mobility studies.
The Journal of biological chemistry 1999;274(3):1606-13.
1998: Gurwitz D; Kloog Y
Do endogenous cannabinoids contribute to HIV-mediated immune failure?
Molecular medicine today 1998;4(5):196-200.
1998: Aharonson Z; Gana-Weisz M; Varsano T; Haklai R; Marciano D; Kloog Y
Stringent structural requirements for anti-Ras activity of S-prenyl analogues.
Biochimica et biophysica acta 1998;1406(1):40-50.
1998: Haklai R; Weisz M G; Elad G; Paz A; Marciano D; Egozi Y; Ben-Baruch G; Kloog Y
Dislodgment and accelerated degradation of Ras.
Biochemistry 1998;37(5):1306-14.
1997: Gana-Weisz M; Haklai R; Marciano D; Egozi Y; Ben-Baruch G; Kloog Y
The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation.
Biochemical and biophysical research communications 1997;239(3):900-4.
1996: Tisch D; Halpern M; Marciano D; Kloog Y; Aviram I
Activation of signaling pathways in HL60 cells and human neutrophils by farnesylthiosalicylate.
European journal of biochemistry / FEBS 1996;242(3):529-36.
1995: Marom M; Haklai R; Ben-Baruch G; Marciano D; Egozi Y; Kloog Y
Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid.
The Journal of biological chemistry 1995;270(38):22263-70.
1995: Marciano D; Ben-Baruch G; Marom M; Egozi Y; Haklai R; Kloog Y
Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth.
Journal of medicinal chemistry 1995;38(8):1267-72.
1994: Marom M; Ben-Baruch G; Roitelman J; Kloog Y
Lack of correlation between 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and lovastatin resistance in nerve growth factor treated PC-12 cells.
Cellular and molecular neurobiology 1994;14(2):119-32.
1993: Paz A; Ben-Baruch G; Marciano D; Egozi Y; Haklai R; Kloog Y
Prenylated protein methyltransferase of rat cerebellum is developmentally co-expressed with its substrates.
FEBS letters 1993;332(3):215-7.
1993: Ben Baruch G; Paz A; Marciano D; Egozi Y; Haklai R; Kloog Y
The uniquely distributed isoprenylated protein methyltransferase activity in the rat brain is highly expressed in the cerebellum.
Biochemical and biophysical research communications 1993;195(1):282-8.
1993: Haklai R; Lerner S; Kloog Y
Nerve growth factor induces a succession of increases in isoprenylated methylated small GTP-binding proteins of PC-12 pheochromocytoma cells.
Neuropeptides 1993;24(1):11-25.
1992: Lerner S; Haklai R; Kloog Y
Isoprenylation and carboxylmethylation in small GTP-binding proteins of pheochromocytoma (PC-12) cells.
Cellular and molecular neurobiology 1992;12(4):333-51.
1992: Wollberg Z; Bousso-Mittler D; Bdolah A; Kloog Y; Kochva E; Sokolovsky M
Endothelins and sarafotoxins: effects on motility, binding properties and phosphoinositide hydrolysis during the estrous cycle of the rat uterus.
Journal of basic and clinical physiology and pharmacology 1992;3(1):41-57.
1991: Solomon R; Ben Baruch G; Menczer J; Kloog Y
Downregulation of specific protein carboxylmethyltransferase immunoreactivity in human endometrial carcinoma.
Cancer 1991;68(8):1742-6.
1991: Haklai R; Kloog Y
Relationship among methylation, isoprenylation, and GTP binding in 21- to 23-kDa proteins of neuroblastoma.
Cellular and molecular neurobiology 1991;11(4):415-33.
1991: Galron R; Bdolah A; Kochva E; Wollberg Z; Kloog Y; Sokolovsky M
Kinetic and cross-linking studies indicate different receptors for endothelins and sarafotoxins in the ileum and cerebellum.
FEBS letters 1991;283(1):11-4.
1990: Haklai R; Kloog Y
Methylation of 21-23 kD membrane proteins by a membrane-associated protein carboxyl methyltransferase in neuroblastoma cells. Increased methylation in differentiated cells.
Biochemical pharmacology 1990;40(6):1365-72.
1990: Galron R; Bdolah A; Kloog Y; Sokolovsky M
Endothelin/sarafotoxin receptor induced phosphoinositide turnover: effects of pertussis and cholera toxins and of phorbol ester.
Biochemical and biophysical research communications 1990;171(3):949-54.
1990: Ambar I; Kloog Y; Sokolovsky M
Cross-linking of endothelin 1 and endothelin 3 to rat brain membranes: identification of the putative receptor(s).
Biochemistry 1990;29(27):6415-8.
1990: Skolovsky M; Galron R; Kloog Y; Bdolah A; Indig F E; Blumberg S; Fleminger G
Endothelins are more sensitive than sarafotoxins to neutral endopeptidase: possible physiological significance.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(12):4702-6.
1990: Kloog Y; Lamdani-Itkin H; Sokolovsky M
The glycine site of the N-methyl-D-aspartate receptor channel: differences between the binding of HA-966 and of 7-chlorokynurenic acid.
Journal of neurochemistry 1990;54(5):1576-83.
1990: Lamdani-Itkin H; Kloog Y; Sokolovsky M
Modulation of glutamate-induced uncompetitive blocker binding to the NMDA receptor by temperature and by glycine.
Biochemistry 1990;29(16):3987-93.
1990: Ikin A F; Kloog Y; Sokolovsky M
N-methyl-D-aspartate/phencyclidine receptor complex of rat forebrain: purification and biochemical characterization.
Biochemistry 1990;29(9):2290-5.
1990: Nadler V; Kloog Y; Sokolovsky M
Distinctive structural requirement for the binding of uncompetitive blockers (phencyclidine-like drugs) to the NMDA receptor.
European journal of pharmacology 1990;188(2-3):97-104.
1990: Haklai R; Kloog Y
Carboxyl methylation of 21-23 kDa membrane proteins in intact neuroblastoma cells is increased with differentiation.
FEBS letters 1990;259(2):233-6.
1990: Galron R; Kloog Y; Bdolah A; Sokolovsky M
Different pathways of endothelin/sarafotoxin-stimulated phosphoinositide hydrolysis in myocytes.
European journal of pharmacology 1990;188(1):85-8.
1990: Ikin A F; Nadler V; Kloog Y; Sokolovsky M
Characterization of membranal and purified NMDA receptors.
Advances in experimental medicine and biology 1990;268():109-14.
1989: Feigenbaum J J; Bergmann F; Richmond S A; Mechoulam R; Nadler V; Kloog Y; Sokolovsky M
Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(23):9584-7.
1989: Bdolah A; Wollberg Z; Ambar I; Kloog Y; Sokolovsky M; Kochva E
Disturbances in the cardiovascular system caused by endothelin and sarafotoxin.
Biochemical pharmacology 1989;38(19):3145-6.
1989: Ambar I; Kloog Y; Sokolovsky M
Solubilization of endothelin/sarafotoxin receptors in an active binding form.
European journal of pharmacology 1989;170(1-2):119-20.
1989: Galron R; Kloog Y; Bdolah A; Sokolovsky M
Functional endothelin/sarafotoxin receptors in rat heart myocytes: structure-activity relationships and receptor subtypes.
Biochemical and biophysical research communications 1989;163(2):936-43.
1989: Shimon M; Egozi Y; Kloog Y; Sokolovsky M; Cohen S
Vascular cholinesterases and choline uptake in isolated rat forebrain microvessels: a possible link.
Journal of neurochemistry 1989;53(2):561-5.
1989: Bousso-Mittler D; Kloog Y; Wollberg Z; Bdolah A; Kochva E; Sokolovsky M
Functional endothelin/sarafotoxin receptors in the rat uterus.
Biochemical and biophysical research communications 1989;162(3):952-7.
1989: Kloog Y; Bousso-Mittler D; Bdolah A; Sokolovsky M
Three apparent receptor subtypes for the endothelin/sarafotoxin family.
FEBS letters 1989;253(1-2):199-202.
1989: Fleminger G; Bousso-Mittler D; Bdolah A; Kloog Y; Sokolovsky M
Immunological and structural characterization of sarafotoxin/endothelin family of peptides.
Biochemical and biophysical research communications 1989;162(3):1317-23.
1989: Kloog Y; Ambar I; Kochva E; Wollberg Z; Bdolah A; Sokolovsky M
Sarafotoxin receptors mediate phosphoinositide hydrolysis in various rat brain regions.
FEBS letters 1989;242(2):387-90.
1989: Ambar I; Kloog Y; Schvartz I; Hazum E; Sokolovsky M
Competitive interaction between endothelin and sarafotoxin: Binding and phosphoinositides hydrolysis in rat atria and brain.
Biochemical and biophysical research communications 1989;158(1):195-201.
1988: Egozi Y; Kloog Y; Fleminger G; Sokolovsky M
Acetylcholine in the rat pituitary: a possible humoral factor.
Brain research 1988;475(2):376-9.
1988: Ambar I; Kloog Y; Kochva E; Wollberg Z; Bdolah A; Oron U; Sokolovsky M
Characterization and localization of a novel neuroreceptor for the peptide sarafotoxin.
Biochemical and biophysical research communications 1988;157(3):1104-10.
1988: Solomon R; Katzir O; Egozi Y; Kloog Y
Identification of two distinct protein carboxyl methyltransferases in eucaryotic cells.
FEBS letters 1988;241(1-2):131-5.
1988: Nadler V; Kloog Y; Sokolovsky M
1-Aminocyclopropane-1-carboxylic acid (ACC) mimics the effects of glycine on the NMDA receptor ion channel.
European journal of pharmacology 1988;157(1):115-6.
1988: Kloog Y; Ambar I; Sokolovsky M; Kochva E; Wollberg Z; Bdolah A
Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain.
Science (New York, N.Y.) 1988;242(4876):268-70.
1988: Ambar I; Kloog Y; Sokolovsky M
Solubilization of rat brain phencyclidine receptors in an active binding form that is sensitive to N-methyl-D-aspartate receptor ligands.
Journal of neurochemistry 1988;51(1):133-40.
1988: Shimon M; Egozi Y; Kloog Y; Sokolovsky M; Cohen S
Kinetics of choline uptake into isolated rat forebrain microvessels: evidence of endocrine modulation.
Journal of neurochemistry 1988;50(6):1719-24.
1988: Kloog Y; Nadler V; Sokolovsky M
Mode of binding of [3H]dibenzocycloalkenimine (MK-801) to the N-methyl-D-aspartate (NMDA) receptor and its therapeutic implication.
FEBS letters 1988;230(1-2):167-70.
1988: Kloog Y; Haring R; Sokolovsky M
Kinetic characterization of the phencyclidine-N-methyl-D-aspartate receptor interaction: evidence for a steric blockade of the channel.
Biochemistry 1988;27(3):843-8.
1987: Haring R; Kloog Y; Kalir A; Sokolovsky M
Binding studies and photoaffinity labeling identify two classes of phencyclidine receptors in rat brain.
Biochemistry 1987;26(18):5854-61.
1987: Haklai R; Kloog Y
Purification and characterization of protein carboxyl methyltransferase from Torpedo ocellata electric organ.
Biochemistry 1987;26(14):4200-6.
1983: Haring R; Kloog Y; Kalir A; Sokolovsky M
Species differences determine azido phencyclidine labeling pattern in desensitized nicotinic acetylcholine receptors.
Biochemical and biophysical research communications 1983;113(2):723-9.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Yoel Kloog

Research Profile (preview)

Chemicals & Drugs

Living Beings

Physiology

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Yoel Kloog (preview)

All Publications